Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 8/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16015620 | 0.91 | OPRM1 (0.46) | OPRM1OPRD1OPRK1 | |
| SCHEMBL21859469 | 0.87 | OPRM1 (0.51) | OPRM1OPRD1OPRK1 | |
| SCHEMBL16015642 | 0.86 | OPRM1 (0.71) | OPRM1OPRD1OPRK1 | |
| SCHEMBL12255374 | 0.82 | OPRM1 (0.74) | OPRM1OPRD1OPRK1 | |
| SCHEMBL16311897 | 0.82 | OPRM1 (0.39) | OPRM1OPRD1OPRK1 | |
| SCHEMBL16311896 | 0.80 | OPRM1 (0.51) | OPRM1OPRD1OPRK1 | |
| SCHEMBL12945147 | 0.78 | OPRM1 (0.73) | OPRM1OPRD1OPRK1 | |
| SCHEMBL14852891 | 0.77 | OPRM1 (0.60) | OPRM1OPRD1OPRK1 | |
| SCHEMBL16188984 | 0.76 | OPRM1 (0.54) | OPRM1OPRD1OPRK1 | |
| SCHEMBL15337225 | 0.75 | OPRM1 (0.55) | OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9518062-B2 | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers | MALLINCKRODT LLC (US) | 2016-12-13 | — | — | US | disclosed |
| US-20140370005-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS | SpecGx LLC | 2014-12-18 | — | — | US | disclosed |
| US-8829020-B2 | Compounds and compositions for use in phototherapy and in treatment of ocular neovascular disease and cancers | MALLINCKRODT LLC (US) | 2014-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140370005-A1 | COMPOUNDS AND COMPOSITIONS FOR USE IN PHOTOTHERAPY AND IN TREATMENT OF OCULAR NEOVASCULAR DISEASE AND CANCERS | VEGFA, OPRL1, OGFR | OPRM1 5/4885OPRD1 9/4885OPRK1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.